Literature DB >> 4857542

An alkylating agent-globulin conjugate with both alkylating and antibody activity.

J H Lindford, G Froese, I Berczi, L G Israels.   

Abstract

Mesh:

Substances:

Year:  1974        PMID: 4857542     DOI: 10.1093/jnci/52.5.1665

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Antibodies as specific carriers for chemotherapeutic agents.

Authors:  F H Lee; K M Hwang
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Experimental studies on specific immunotherapy in nasopharyngeal carcinoma (NPC).

Authors:  W Arnold; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1980

3.  Tumour cell-antibody interactions. I. In vivo experiments.

Authors:  G Froese; I Berczi; L G Israels
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

4.  Tumour cell-antibody interactions. II. In vitro studies.

Authors:  G Froese; I Berczi; L G Israels
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

Review 5.  Oncostatic-antibody complexes in chemotherapy.

Authors:  H F Dullens; R A De Weger
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Inhibition of a mouse hepatoma by the alkylating agent Trenimon linked to immunoglobulins.

Authors:  T Ghose; A Guclu; R R Raman; A H Blair
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.